LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION April 23, 2023 TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB1150 by Menndez (Relating to prior authorization for prescription drug benefits related to the treatment of chronic and autoimmune diseases.), As Introduced No significant fiscal implication to the State is anticipated.Based on information provided by The Texas University System and the Texas A&M System, implementation of the bill could impact medical plans resulting in a significant costs to institutional funds. Institutional Funds are not appropriated in the General Appropriations Act, and therefore not a cost to the State. The bill would amend the Insurance Code to prohibit a health benefit plan from requiring an enrollee to obtain more than one prior authorization annually of the prescription drug benefit for a prescription drug prescribed to treat a chronic or autoimmune disease. It is assumed any costs associated with the bill would be implemented within existing resources. Based on information provided by The Texas University System and the Texas A&M System, implementation of the bill could impact medical plans resulting in a significant costs to institutional funds. Institutional Funds are not appropriated in the General Appropriations Act, and therefore not a cost to the State. Local Government ImpactNo significant fiscal implication to units of local government is anticipated. Source Agencies: b > td > 323 Teacher Retirement System, 327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission, 710 Texas A&M University System Administrative and General Offices, 720 The University of Texas System Administration LBB Staff: b > td > JMc, NPe, GO, AAL, JSM, JPO
LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION
April 23, 2023
TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB1150 by Menndez (Relating to prior authorization for prescription drug benefits related to the treatment of chronic and autoimmune diseases.), As Introduced
TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
FROM: Jerry McGinty, Director, Legislative Budget Board
IN RE: SB1150 by Menndez (Relating to prior authorization for prescription drug benefits related to the treatment of chronic and autoimmune diseases.), As Introduced
Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
Jerry McGinty, Director, Legislative Budget Board
Jerry McGinty, Director, Legislative Budget Board
SB1150 by Menndez (Relating to prior authorization for prescription drug benefits related to the treatment of chronic and autoimmune diseases.), As Introduced
SB1150 by Menndez (Relating to prior authorization for prescription drug benefits related to the treatment of chronic and autoimmune diseases.), As Introduced
No significant fiscal implication to the State is anticipated.Based on information provided by The Texas University System and the Texas A&M System, implementation of the bill could impact medical plans resulting in a significant costs to institutional funds. Institutional Funds are not appropriated in the General Appropriations Act, and therefore not a cost to the State.
No significant fiscal implication to the State is anticipated.Based on information provided by The Texas University System and the Texas A&M System, implementation of the bill could impact medical plans resulting in a significant costs to institutional funds. Institutional Funds are not appropriated in the General Appropriations Act, and therefore not a cost to the State.
The bill would amend the Insurance Code to prohibit a health benefit plan from requiring an enrollee to obtain more than one prior authorization annually of the prescription drug benefit for a prescription drug prescribed to treat a chronic or autoimmune disease. It is assumed any costs associated with the bill would be implemented within existing resources. Based on information provided by The Texas University System and the Texas A&M System, implementation of the bill could impact medical plans resulting in a significant costs to institutional funds. Institutional Funds are not appropriated in the General Appropriations Act, and therefore not a cost to the State.
The bill would amend the Insurance Code to prohibit a health benefit plan from requiring an enrollee to obtain more than one prior authorization annually of the prescription drug benefit for a prescription drug prescribed to treat a chronic or autoimmune disease. It is assumed any costs associated with the bill would be implemented within existing resources.
Based on information provided by The Texas University System and the Texas A&M System, implementation of the bill could impact medical plans resulting in a significant costs to institutional funds. Institutional Funds are not appropriated in the General Appropriations Act, and therefore not a cost to the State.
Local Government Impact
No significant fiscal implication to units of local government is anticipated.
Source Agencies: b > td > 323 Teacher Retirement System, 327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission, 710 Texas A&M University System Administrative and General Offices, 720 The University of Texas System Administration
323 Teacher Retirement System, 327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission, 710 Texas A&M University System Administrative and General Offices, 720 The University of Texas System Administration
LBB Staff: b > td > JMc, NPe, GO, AAL, JSM, JPO
JMc, NPe, GO, AAL, JSM, JPO